The dipeptidyl peptidase-4 inhibitor alogliptin improves glycemic control in type 2 diabetic patients undergoing hemodialysis

Expert Opinion on Pharmacotherapy

Volumn 14, Issue 3, 2013, Pages 259-267

  Fujii, Yuki ^a   Abe, Masanori ^a   Higuchi, Terumi ^b   Mizuno, Mari ^b   Suzuki, Hiroko ^a   Matsumoto, Shiro ^a   Ito, Midori ^a   Maruyama, Noriaki ^a   Okada, Kazuyoshi ^a   Soma, Masayoshi ^a  

^a NIHON UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b Keiai Hospital   (Japan)

Author keywords

Alogliptin; Dipeptidyl peptidase 4 inhibitor; Glycemic control; Hemodialysis; Type 2 diabetes

Indexed keywords

ALBUMIN; ALOGLIPTIN; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; CHOLESTEROL; ERYTHROPOIETIN; GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MITIGLINIDE; NITROGEN; PHOSPHATE BINDING AGENT; PROTEIN; VOGLIBOSE;

AGED; ALBUMIN BLOOD LEVEL; ANEMIA; ANTIDIABETIC ACTIVITY; ARTICLE; BODY MASS; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; DIABETIC PATIENT; DIASTOLIC BLOOD PRESSURE; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG SAFETY; DRY WEIGHT; FEMALE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; GROUPS BY AGE; HEART THORAX INDEX; HEMODIALYSIS; HEMODIALYSIS PATIENT; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; LIVER DYSFUNCTION; MALE; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; PROTEIN BLOOD LEVEL; SIDE EFFECT; SYSTOLIC BLOOD PRESSURE; UREA NITROGEN BLOOD LEVEL;

AGED; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; DRUG THERAPY, COMBINATION; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; MALE; PIPERIDINES; PROSPECTIVE STUDIES; RENAL DIALYSIS; SERUM ALBUMIN; URACIL;

EID: 84873371251     PISSN: 14656566     EISSN: 17447666     Source Type: Journal    
DOI: 10.1517/14656566.2013.761690     Document Type: Article

References (27)

1. Abe M, Okada K, Soma M. Antidiabetic agents in patients with chronic kidney disease and end-Stage renal disease on dialysis: Metabolism and clinical practice. Curr Drug Metab 2011;12:57-69
2. Yale JF. Oral antihyperglycemic agents and renal disease: New agents, new concepts. J Am Soc Nephrol 2005;16:7-10
3. Drucker DJ, Nauck MA. The incretin system: Glucagon-Like peptide-1 receptor agonists and dipeptidyl peptidase-IV inhibitors in type 2 diabetes. Lancet 2006;368:1696-705 (Pubitemid 46048557)
4. Sheen AJ. Pharmacokinetics of dipeptidylpeptidase-4 inhibitors. Diabetes Obes Metab 2010;12:648-58
5. Idris S, Donnelly R. Dipeptidyl peptidase-IV inhibitors: A major new class of oral antidiabetic drug. Diab Obes Metab 2007;9:153-65 (Pubitemid 46206559)
6. DeFronzo RA, Fleck PR, Wilson CA, et al. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes and inadequate glycemic control: A randomized double-blind, placebo-Controlled study. Diabetes Care 2008;31:2315-17
7. Pratley RE, Reuxch JE, Fleck PR, et al. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin added to pioglitazone in patients with type 2 diabetes: A randomized, double-blind, placebo-Controlled study. Curr Med Res Opin 2009;25:2361-71
8. Pratley RE, Kipnes MS, Fleck PR, et al. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes inadequately controlled by glyburide monotherapy. Diabet Obes Metab 2009;11:167-76
9. Nauck MA, Ellis GC, Fleck PR, et al. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin to metformin therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy: A multicenter, randomized, double-blind, placebo-Controlled study. Int J Clin Pract 2009;63:46-55
10. Rosenstock J, Rendell MS, Gross JL, et al. Alogliptin added to insulin therapy in patients with type 2 diabetes reduces HbA1c without causing weight gain or increased hypoglycemia. Diabets Obes Metab 2009;11:1145-52
11. Pratley RE, McCall T, Fleck PR, et al. Alogliptin use in elderly people: A pooled analysis from phase 2 and 3 studies. J Am Geriatr Soc 2009;57:2011-19
12. Abe M, Okada K, Maruyama T, et al. Efficacy and safety of mitiglinide in diabetic patients on maintenance hemodialysis. Endcrine J 2010;57:581-8
13. Yu L, Lu S, Lin Y, et al. Carboxyl-glucuronidation of mitiglinide by human UDP-glucuronosyltransferases. Biochem. Pharmacol 2010;73:1842-51 (Pubitemid 46601408)
14. Narita T, Katsuura Y, Sato T, et al. Miglitol induces prolonged and enhanced glucagon-Like peptide-1 and reduced gastric inhibitory polypeptide responses after ingestion of a mixed meal in Japanese type 2 diabetic patients. Diabet Med 2009;26:187-8
15. Seino Y, Fujita T, Hiroi S, et al. Alogliptin plus voglibose in Japanese patients with type 2 diabetes: A randomized, double-blind, placebo-Controlled trial with an open-Label, long-Term extension. Curr Med Res Opin 2011 ;27:S3 21-9
16. Christopher R, Covington P, Davenport M, et al. Pharmacokinetic, pharmacodynamics, and tolerability of single increasing dose of the dipeptidyl peptidase-4 inhibitor alogliptin in healthy male subjects. Clin Ther 2008;30:513-27 (Pubitemid 351492530)
17. Covington P, Christopher R, Davenport M, et al. Pharmacokinetic, pharmacodynamics, and tolerability profiles of the dipeptidyl peptidase-4 inhibitor alogliptin: A randomized, double-blind, placebo-Controlled, multiple-Dose study in adult patients with type 2 diabetes. Clin Ther 2008;30:499-512 (Pubitemid 351483925)
18. Scott LJ. Alogliptin: A review of its use in the management of type 2 diabetes mellitus. Drugs 2010;70:2051-72
19. Kidney Disease Outcomes Quality Initiative (KDOQI). Clinical practice guidelines and clinical practice recommendations for diabetes and chronic kidney disease. Am J Kidney Dis 2007;49:S62-73
20. 2007 American Diabetes Association. Standards of medical care in diabetes-2008. Diabetes Care 2008;31:S12-54
21. Inaba M, Okuno S, Kumeda Y, et al. Glycated albumin is a better glycemic indicator than glycated hemoglobin values in hemodialysis patients with diabetes: Effect of anemia and erythropoietin injection. J Am Soc Nephrol 2007;18:896-903 (Pubitemid 46434506)
22. Peacock TP, Shihabi ZK, Bleyer AJ, et al. Comparison of glycated albumin and hemoglobin A1c levels in diabetic subjects on hemodialysis. Kidney Int 2008;73:1062-8 (Pubitemid 351543905)
23. Abe M, Matsumoto K. Glycated hemoglobin or glycated albumin for assessment of glycemic control in dialysis patients with diabetes? Nat Clin Pract Nephrol 2008;4:482-3
24. Shima K, Komatsu M, Kawahara K, et al. Stringent glycemic control prolongs survival in diabetic patients with end-Stage renal disease on hemodialysis. Nephrology 2010;15:632-8
25. Barnett A. DPP-4 inhibitors and their potential role in the management of type 2 diabetes. Int J Clin Pract 2006;60:1454-70 (Pubitemid 44560347)
26. Mathieu C, Bollaerts K. Antihyperglycemic therapy in elderly patients with type 2 diabetes: Potential role of incretin mimetics and DPP-4 inhibitors. Int J Clin Pract 2007;61:29-37 (Pubitemid 46934640)
27. Pratley RE, Rosenstock J, Pi-Sunyer FX, et al. Management of type 2 diabetes in treatment-naive elderly patients. Diabetes Care 2007;30:3017-22